New PrevahexCHX™ is the first and only CHX dressing cleared by the FDA with complete antimicrobial protection throughout the transparent areas of the dressing. PrevahexCHX antimicrobial dressing incorporate groundbreaking technology utilizing pure chlorhexidine, providing rapid, broad-spectrum dressing protection at wound and catheter sites.
New evidence shows that catheter-related bloodstream infections (CRBSIs) and surgical site infections (SSIs) continue to cause unnecessary illness, healthcare costs and death in hospitals across the country. Research suggests that to better protect our patients, we may need to alter our approach.1
healthcare associated infections annually2
unnecessary healthcare costs2
1 Ryder, Marcia PhD. Healthcare Acquired Infections: Unfortunate Complication or Medical Error. Journal of Consumer Attorneys Associations for Southern California Advocate. July 2016
2 Stone, Patricia. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. October 2009; 9(5): pp. 417-422
3 Maki, D.G. Weise, C.E. Sarafin, H.W. A semiquantitative culture method for identifying intravenous-catheter-related infection. New England Journal of Medicine. 1977; 296(23): pp. 1305-1309. Maki, D.G. Alvarado, C.J. Ringer, M. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. The Lancet. 1991; 338(8763): pp. 339-343
4 Karpanen, T. Worthington, T. Conway, B. Hilton, C. Elliot, T. and Lambert, P. Penetration of Chlorhexidine into Human Skin. Antimicrobial Agents and Chemotherapy. October 2008; pp. 3633-3636
5 Reference: Maki, D.G., Cobb, L., Garman, J.K., Shapiro, J.M., Ringer, M., Helgerson, R.B. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: A prospective randomized multicenter trial. Am J Med 1988; (85): pp. 307-314.